DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Phase 1

Completed

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: Nilotinib, Imatinib

First Posted Date: 2007-02-28

Last Posted Date: 2013-05-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT00441155

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇮🇹
Novartis Investigative Site, Milano, MI, Italy

Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Valsartan/HCTZ
Drug: HCTZ + Amlodipine

First Posted Date: 2007-02-26

Last Posted Date: 2017-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 412

Registration Number: NCT00439738

Locations: 🇺🇸
Terence T. Hart, MD, Muscle Shoals, Alabama, United States
🇺🇸
Oklahoma Cardiovascular & Hypertension, Oklahoma City, Oklahoma, United States
🇺🇸
Northeast Tarrant Internal Medicine Assoc, Euless, Texas, United States

and more 2 locations

Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis

Phase 3

Completed

Conditions: Male Osteoporosis

Interventions: Drug: Zoledronic acid 5 mg iv
Drug: Placebo

First Posted Date: 2007-02-23

Last Posted Date: 2017-04-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1199

Registration Number: NCT00439647

Locations: 🇬🇧
Novartis Investigative Site, Penarth, United Kingdom
🇬🇧
Novartis Investigative site, Reading-Berkshire, United Kingdom
🇸🇪
Novartis investigative site, Uppsala, Sweden

Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis

Phase 3

Completed

Conditions: Chronic Plaque Psoriasis

Interventions: Drug: Cyclosporine A microemulsion
Drug: Placebo

First Posted Date: 2007-02-22

Last Posted Date: 2011-08-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 243

Registration Number: NCT00438360

Locations: 🇮🇹
Novartis Investigative Site, Bari, Italy

Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: Valsartan 160 mg capsules
Drug: Amlodipine 5 mg capsules
Drug: placebo

First Posted Date: 2007-02-21

Last Posted Date: 2014-11-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1183

Registration Number: NCT00437645

Locations: 🇨🇱
sites in Chile, Chile, Chile
🇨🇭
sites in Switzerland, Switzerland, Switzerland
🇪🇨
sites in Ecuador, Ecuador, Ecuador

and more 9 locations

Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Valsartan 4.0 mg/kg
Drug: Valsartan 0.25 mg/kg
Drug: Valsartan 1.0 mg/kg

First Posted Date: 2007-02-14

Last Posted Date: 2011-05-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 74

Registration Number: NCT00435162

Locations: 🇺🇸
Sites in USA, USA, New Jersey, United States
🇮🇳
Sites in India, India, India
🇧🇷
Sites in Brazil, Brazil, Brazil

and more 8 locations

Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients

Phase 4

Terminated

Conditions: Kidney Transplantation

Interventions: Drug: Enteric coated mycophenolate sodium (Myfortic®)

First Posted Date: 2007-02-13

Last Posted Date: 2011-04-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT00434590

Locations: 🇮🇹
Novartis Investigative Site, Bologna, Italy

Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases

Phase 4

Completed

Conditions: Bone Neoplasms

Interventions: Drug: Zoledronic acid

First Posted Date: 2007-02-13

Last Posted Date: 2017-02-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 73

Registration Number: NCT00434447

Locations: 🇦🇺
Novartis Investigative Site, Frankston, Victoria, Australia

Safety of Everolimus and Pemetrexed in Lung Cancer Patients

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Everolimus
Drug: Pemetrexed

First Posted Date: 2007-02-13

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT00434174

Locations: 🇩🇪
Novartis Investigative Site, Koeln, Germany

Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease

Phase 3

Completed

Conditions: Cushing's Disease

Interventions: Drug: Pasireotide

First Posted Date: 2007-02-12

Last Posted Date: 2016-03-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 162

Registration Number: NCT00434148

Locations: 🇹🇷
Novartis Investigative Site, Fatih / Istanbul, Turkey
🇺🇸
Stanford University Medical Center Stanford Cancer Center (3), Stanford, California, United States
🇺🇸
University Chicago Hospital Dept. of Univ of Chicago, Chicago, Illinois, United States

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy